Author(s): Laxman D. Khatal, Harinath N. More

Email(s): lakhan_khatal@yahoo.co.in

DOI: 10.52711/0974-360X.2021.00988   

Address: Laxman D. Khatal*, Harinath N. More
Bharati Vidyapeeth College of Pharmacy, Kolhapur, Near Chitranagri, Kolhapur - 416013, Maharashtra, India.
*Corresponding Author

Published In:   Volume - 14,      Issue - 11,     Year - 2021


ABSTRACT:
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR), primarily used to treat non-small cell lung cancer (NSCLC) or pancreatic cancer. The main objective of the present study was to identify differences and similarities in the metabolism of erlotinib across various species and to identify new phase I metabolites. Metabolic characteristics of erlotinib were investigated in liver microsomes of human, mice, rat, dog, hamster, and S9-fraction of mice by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A total of 19 phase I metabolites were detected in human liver microsomes; whereas, 12 metabolites in each of mice-, rat- liver microsomes and S9-fraction of mice; 10 in dog liver microsomes and 7 in hamster liver microsomes were detected. Out of these 19 metabolites, 8 metabolites were newly found including 1- novel metabolite (M23) which was identified with its putative structure in human liver microsomes. All phase I metabolites reported in healthy human volunteers were identified in human liver microsomes. Similar metabolic behavior had shown by liver microsomes of mice, rat, and S9-fraction of mice. Metabolites M6, M13, M14, M16, M22, and M25 were found in all tested species. These differences and similarities in the metabolism of erlotinib confirmed the role of CYP 450 enzymes and their distinct activity across various species.


Cite this article:
Laxman D. Khatal, Harinath N. More. Differences and Similarities in the Metabolism of Erlotinib across various Species: An Analysis by Liquid Chromatography - Tandem Mass Spectrometry. Research Journal of Pharmacy and Technology. 2021; 14(11):5683-0. doi: 10.52711/0974-360X.2021.00988

Cite(Electronic):
Laxman D. Khatal, Harinath N. More. Differences and Similarities in the Metabolism of Erlotinib across various Species: An Analysis by Liquid Chromatography - Tandem Mass Spectrometry. Research Journal of Pharmacy and Technology. 2021; 14(11):5683-0. doi: 10.52711/0974-360X.2021.00988   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-11-13


REFERENCES:
1.    Ravindran S, et al. Significance of Biotransformation in Drug Discovery and Development. Biotechnology and Biomaterials 2012; S13: 005.
2.    Vangala S, et al. Translational Drug Discovery Research: Integration of Medicinal Chemistry, Computational Modeling, Pharmacology, ADME, and Toxicology. Encyclopedia of Drug Metabolism and Interactions. 2012; 1-54.
3.    U.S. Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research. Guidance for industry, Safety testing of drug metabolites 2016.
4.    European Medicines Agency. ICH Topic M3 (R2), Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals 2008; CPMP/ICH/286/95.
5.    Waill AE, et al. Molecular Identification, Metabolites profiling, Anti-breast cancer, Anti-colorectal cancer, and antioxidant potentials of Streptomyces zaomyceticus AA1 isolated from a remote bat cave in Egypt. Research  J. Pharm. and Tech. 2020; 13(7): 3072-3080.
6.    Sumathi R, et al. Isolation, purification, partial characterization and antibacterial activities of compound produced by some actinomycetes from sedimented waters. Research J. Pharm. and Tech. 2009; 2(4): 783-788.
7.    Anna S, et al. A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. J. Pharm. Biomed. Anal. 2015; 107: 186-195.
8.    Ling J, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab. Dispos. 2006; 34: 420-426.
9.    Johnson K, Prakash C. Identifcation of Phase I and Phase II metabolites of CP358774, using ESI/LC/MS and LC/MS/MS in beagle dogs. 46th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando Fl. 1998; May 31-Jun 4.
10.    Lepper ER, et al. Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J. Chromatogr. B. Biomed. Appl. 2003; 796: 181-188.
11.    Zhang W, et al. Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J. Chromatogr. B. Biomed. Appl. 2005; 814: 143-147.
12.    Mohammed I, et al. Analytical Method Development and Validation of Erlotinib by High Performance Liquid Chromatography. Research J. Pharm. and Tech. 2011; 4(11): 1787-1790.
13.    Masters AR, et al. The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Biomed. Appl. 2007; 796: 379-383.
14.    Zhao M, et al. Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Biomed. Appl. 2003; 793: 413-20.
15.    Rodriguez J, et al. Simultaneous determination of erlotinib and metabolites in human urine using capillary electrophoresis. Electrophoresis 2014; 35: 1489-1495.
16.    Feng W, et al. In vitro Drug Metabolism Investigation of 7-Ethoxycoumarin in Human, Monkey, Dog and Rat Hepatocytes by High Resolution LC-MS/MS. Drug Metab. Lett. 2018; 12: 33-53.
17.    Selvan R, et al. Differences and Similarities in  the Metabolism of Glyburide for Various Species: An Analysis by LC-DAD-Q-TRAP-MS/MS. J. Anal. Bioanal. Tech. 2013; 4:164.
18.    Zhang Z, et al. Characterization of the in Vitro Metabolic Profile of Evodiamine in Human Liver Microsomes and Hepatocytes by UHPLC-Q Exactive Mass Spectrometer. Front Pharmacol. 2018; 9: 130.
19.    Akasha R, et al. Characterization of the global metabolic profile of Canagliflozin in Rat plasma, urine and feces based on HPLCUV-MS Analysis. Res. J. Pharm. and Tech. 2020; 13: 399-403.
20.    Sabreen K, et al. Characterization of Antifungal Metabolites Produced by Aeromonas Hydrophila and Analysis of its Chemical Compounds Using GC-MS. Res. J. Pharm. and Tech. 2017; 10: 3845-51.
21.    Phale M, Korgaonkar D. Current Advance Analytical Techniques: A Review. Asian J. Research Chem. 2009; 2(3): 235-238.
22.    Khan H, et al. Validated UPLC/Q-TOF-MS Method for Simultaneous Determination of Telmisartan and Hydrochlorothiazide in Human Plasma. Research J. Pharm. and Tech. 2016; 9(9):1441-1446.
23.    Bhole RP, et al. Liquid Chromatography-Mass Spectrometry Technique-A Review. Research J. Pharm. and Tech. 2020; 13(1): 505-516.
24.    Pramod K, et al. An Overview: LC-MS as Tool of sample Extraction and Quantification in Bioanalytical Laboratories. Asian J. Pharm. Ana. 2020; 10(3):165-172.
25.    Naidu YK, et al. Quantification of Levetiracetam in Human Plasma with Precipitation Extraction by Using Fully Validated LC-MS/MS and Its Application to a Bioequivalence Study. Research J. Pharm. and Tech. 2010; 3(3): 847-853.
26.    Halde S, et al. Determination of Emtricitabine in Human Plasma by LC-MS/MS. Research  J. Pharm. and Tech. 2012; 5(1): 133-137.
27.    Reddy S, et al. Development and Validation of two LCMS/MS Methods for Simultaneous Estimation of Oseltamivir and its Metabolite in Human Plasma and Application in Bioequivalence Study. Asian J. Pharm. Ana. 2016; 6(2): 91.
28.    Prathyusha V, Palani S. Determination of Riluzole in Human Plasma by Ultra Performance Liquid Chromatography – Tandem Mass Spectrometry (UPLC – MS/MS) and its Application to a Pharmacokinetic Study. Research J. Pharm. and Tech. 2017; 10(1): 193-199.
29.    Francis M, et al. Development and Validation of Highly Sensitive HPLC-Ms/Ms Method for the Determination of Duloxetine in Human Plasma and its Application to Clinical Pharmacokinetic Study by Assessing Multiple Bioequivalence Approaches. Research J. Pharm. and Tech. 2020; 13(5): 2117-2124.
30.    Sambasiva Rao P, G Nithya. Sensitive method for the Determination of Colchicine in human plasma by gradient UPLC-ESI-MS/MS: separation of endogenous Interference. Research J. Pharm. and Tech. 2020.
31.    Vishnu K, et al. A Sensitive Liquid Chromatography-tandem Mass Spectrometry Method for the Estimation of Cilostazol in Bulk and in a Pharmaceutical Formulation. Research J. Pharm. and Tech. 2019; 12(6): 2781-2783.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available